VIENNA, Va., March 30 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION is pleased to announce that it expects to file its 10-K in early April, 2006, and the quarterly report for the period ending December 31, 2005 quickly thereafter. Recently, the Company’s auditor for the years through 2004 authorized the Company to submit the 10-K to the Company’s current auditor for what is expected to be the final review prior to filing the 10-K with the SEC. CEL-SCI’s management is hopeful that this will occur during the first week of April, but the timelines are not under CEL-SCI’s control. CEL- SCI has communicated this information to the American Stock Exchange.
CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has operations in Vienna, Virginia and Baltimore, Maryland.
When used in this report, the words “intends,” “plans,” “believes,” “anticipated” and “expects” and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties, which could cause actual results to differ materially from those projected. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
CEL-SCI Corporation
CONTACT: COMPANY CONTACT: Gavin de Windt of CEL-SCI Corporation,+1-703-506-9460; or INVESTOR RELATIONS: Mike Lucci of Lucci FinancialGroup, LLC, +1-248-723-3330, for CEL-SCI Corporation
Web site: http://www.cel-sci.com/
